{"id": "article-29474_0", "title": "Steatorrhea -- Continuing Education Activity", "content": "The management of steatorrhea is complex and new approaches have been introduced. To achieve satisfactory outcomes, the basic and clinical aspects of steatorrhea must be clearly defined. This activity reviews the evaluation and management of steatorrhea and highlights the role of the interprofessional team in evaluating and improving care for patients suffering from steatorrhea.", "contents": "Steatorrhea -- Continuing Education Activity. The management of steatorrhea is complex and new approaches have been introduced. To achieve satisfactory outcomes, the basic and clinical aspects of steatorrhea must be clearly defined. This activity reviews the evaluation and management of steatorrhea and highlights the role of the interprofessional team in evaluating and improving care for patients suffering from steatorrhea."}
{"id": "article-29474_1", "title": "Steatorrhea -- Continuing Education Activity", "content": "Objectives: Identify the etiology of steatorrhea. Describe the clinical features of steatorrhea. Review the management of steatorrhea. Identify interprofessional team strategies for improving care coordination and outcomes in patients suffering from steatorrhea. Access free multiple choice questions on this topic.", "contents": "Steatorrhea -- Continuing Education Activity. Objectives: Identify the etiology of steatorrhea. Describe the clinical features of steatorrhea. Review the management of steatorrhea. Identify interprofessional team strategies for improving care coordination and outcomes in patients suffering from steatorrhea. Access free multiple choice questions on this topic."}
{"id": "article-29474_2", "title": "Steatorrhea -- Introduction", "content": "The definition of steatorrhea is an increase\u00a0in fat excretion in the\u00a0stools. Steatorrhea is one of the clinical features of fat malabsorption and\u00a0noted in many conditions\u00a0such as exocrine pancreatic insufficiency (EPI), celiac disease, and\u00a0tropical sprue.\u00a0An increase in the\u00a0fat content of\u00a0stools results in the production of pale, large volume,\u00a0malodorous, loose stools. Screening for steatorrhea may be carried out by examining stool samples for\u00a0the presence of fat\u00a0by Sudan III staining. However, quantitative fecal fat estimation is\u00a0required to\u00a0confirm the diagnosis.", "contents": "Steatorrhea -- Introduction. The definition of steatorrhea is an increase\u00a0in fat excretion in the\u00a0stools. Steatorrhea is one of the clinical features of fat malabsorption and\u00a0noted in many conditions\u00a0such as exocrine pancreatic insufficiency (EPI), celiac disease, and\u00a0tropical sprue.\u00a0An increase in the\u00a0fat content of\u00a0stools results in the production of pale, large volume,\u00a0malodorous, loose stools. Screening for steatorrhea may be carried out by examining stool samples for\u00a0the presence of fat\u00a0by Sudan III staining. However, quantitative fecal fat estimation is\u00a0required to\u00a0confirm the diagnosis."}
{"id": "article-29474_3", "title": "Steatorrhea -- Introduction", "content": "Among the macronutrients, digestion and absorption of fat involve a complex mechanism. Fat absorption requires bile acids, digestive enzymes, and a normally functioning small intestinal mucosa. Dietary lipids, mostly as triacylglycerols,\u00a0are initially emulsified by bile\u00a0acids\u00a0and then hydrolyzed by the pancreatic lipases and colipases into free fatty acids and monoglycerides. In the proximal small bowel, these hydrolyzed lipids form micelles by the action of bile acids. The\u00a0micelles are then absorbed across the intestinal villi and transported as chylomicrons via the intestinal lymphatics. Therefore, any\u00a0defects in the availability or function\u00a0of bile acids, pancreatic digestive enzymes, or absorptive villi\u00a0will lead to steatorrhea. [1]", "contents": "Steatorrhea -- Introduction. Among the macronutrients, digestion and absorption of fat involve a complex mechanism. Fat absorption requires bile acids, digestive enzymes, and a normally functioning small intestinal mucosa. Dietary lipids, mostly as triacylglycerols,\u00a0are initially emulsified by bile\u00a0acids\u00a0and then hydrolyzed by the pancreatic lipases and colipases into free fatty acids and monoglycerides. In the proximal small bowel, these hydrolyzed lipids form micelles by the action of bile acids. The\u00a0micelles are then absorbed across the intestinal villi and transported as chylomicrons via the intestinal lymphatics. Therefore, any\u00a0defects in the availability or function\u00a0of bile acids, pancreatic digestive enzymes, or absorptive villi\u00a0will lead to steatorrhea. [1]"}
{"id": "article-29474_4", "title": "Steatorrhea -- Etiology", "content": "The causes of steatorrhea are numerous and subclassified under three\u00a0broad categories: Conditions leading to exocrine pancreatic insufficiency (EPI) Bile acid deficiency states Diseases affecting the\u00a0small intestine. Most notable\u00a0disorders\u00a0in each category are\u00a0given below [2] [3] [4] [5] [6] [7] [8] [9] [10] [11] :", "contents": "Steatorrhea -- Etiology. The causes of steatorrhea are numerous and subclassified under three\u00a0broad categories: Conditions leading to exocrine pancreatic insufficiency (EPI) Bile acid deficiency states Diseases affecting the\u00a0small intestine. Most notable\u00a0disorders\u00a0in each category are\u00a0given below [2] [3] [4] [5] [6] [7] [8] [9] [10] [11] :"}
{"id": "article-29474_5", "title": "Steatorrhea -- Etiology", "content": "EPI due to\u00a0chronic pancreatitis, cystic fibrosis (CF), and conditions resulting in pancreatic duct obstruction or resection of the\u00a0pancreas\u00a0(e.g., pancreatic tumors) Bile acid deficiency either due\u00a0to cholestasis e.g. primary biliary cirrhosis,\u00a0currently referred to as primary biliary cholangitis\u00a0(PBC), primary sclerosing cholangitis (PSC), or\u00a0inability to\u00a0absorb\u00a0bile acids\u00a0in the distal\u00a0ileum resulting in diminished bile acid pool e.g. ileal resection or\u00a0Crohn disease of the ileum or deconjugation of bile acids e.g., small\u00a0intestinal bacterial overgrowth (SIBO) Diseases affecting\u00a0proximal\u00a0small intestines such as celiac disease, tropical sprue, giardiasis, Whipple disease, lymphoma, amyloidosis, SIBO, and HIV enteropathy", "contents": "Steatorrhea -- Etiology. EPI due to\u00a0chronic pancreatitis, cystic fibrosis (CF), and conditions resulting in pancreatic duct obstruction or resection of the\u00a0pancreas\u00a0(e.g., pancreatic tumors) Bile acid deficiency either due\u00a0to cholestasis e.g. primary biliary cirrhosis,\u00a0currently referred to as primary biliary cholangitis\u00a0(PBC), primary sclerosing cholangitis (PSC), or\u00a0inability to\u00a0absorb\u00a0bile acids\u00a0in the distal\u00a0ileum resulting in diminished bile acid pool e.g. ileal resection or\u00a0Crohn disease of the ileum or deconjugation of bile acids e.g., small\u00a0intestinal bacterial overgrowth (SIBO) Diseases affecting\u00a0proximal\u00a0small intestines such as celiac disease, tropical sprue, giardiasis, Whipple disease, lymphoma, amyloidosis, SIBO, and HIV enteropathy"}
{"id": "article-29474_6", "title": "Steatorrhea -- Etiology", "content": "Other rare\u00a0causes of steatorrhea include\u00a0lipase inhibitors such as orlistat, Zollinger-Ellison syndrome (increased production of gastric acid inactivates the pH-sensitive\u00a0pancreatic lipases), and graft-versus-host disease. [3]", "contents": "Steatorrhea -- Etiology. Other rare\u00a0causes of steatorrhea include\u00a0lipase inhibitors such as orlistat, Zollinger-Ellison syndrome (increased production of gastric acid inactivates the pH-sensitive\u00a0pancreatic lipases), and graft-versus-host disease. [3]"}
{"id": "article-29474_7", "title": "Steatorrhea -- Epidemiology", "content": "In the\u00a0early stages, steatorrhea may be unrecognized by many patients due to minimal or nonspecific presenting symptoms. Therefore, the\u00a0exact\u00a0prevalence\u00a0and incidence of steatorrhea\u00a0are challenging to estimate and often go underreported. Also, the epidemiology of steatorrhea\u00a0depends on the epidemiology of\u00a0various\u00a0underlying causes, which is a topic of the discussion below.", "contents": "Steatorrhea -- Epidemiology. In the\u00a0early stages, steatorrhea may be unrecognized by many patients due to minimal or nonspecific presenting symptoms. Therefore, the\u00a0exact\u00a0prevalence\u00a0and incidence of steatorrhea\u00a0are challenging to estimate and often go underreported. Also, the epidemiology of steatorrhea\u00a0depends on the epidemiology of\u00a0various\u00a0underlying causes, which is a topic of the discussion below."}
{"id": "article-29474_8", "title": "Steatorrhea -- Epidemiology", "content": "In adults, chronic pancreatitis is the most common cause of EPI. Chronic pancreatitis\u00a0has an annual\u00a0incidence of approximately 4 per 100000 persons and a prevalence of about 42 per 100000 individuals in the\u00a0U.S. [12] In children,\u00a0CF accounts for most cases of EPI.\u00a0CF is the most common lethal autosomal recessive condition affecting the White population. [13] The approximate prevalence of CF\u00a0is\u00a01 in 3000 births. About 85% of CF patients\u00a0have pancreatic insufficiency. [13]", "contents": "Steatorrhea -- Epidemiology. In adults, chronic pancreatitis is the most common cause of EPI. Chronic pancreatitis\u00a0has an annual\u00a0incidence of approximately 4 per 100000 persons and a prevalence of about 42 per 100000 individuals in the\u00a0U.S. [12] In children,\u00a0CF accounts for most cases of EPI.\u00a0CF is the most common lethal autosomal recessive condition affecting the White population. [13] The approximate prevalence of CF\u00a0is\u00a01 in 3000 births. About 85% of CF patients\u00a0have pancreatic insufficiency. [13]"}
{"id": "article-29474_9", "title": "Steatorrhea -- Epidemiology", "content": "The prevalence of celiac disease is on the rise, and a recent study reported a global seroprevalence of 1.4%. [14] Also, there are differences in the prevalence depending on geographical location. Reports of a biopsy-proven celiac disease show lower prevalence rates in South America and Africa and higher rates in Europe and Oceania. [14] For example, in Europe, Germany has a lower prevalence of celiac disease, and the highest prevalence was in Sweden and Finland. [14] Celiac disease has a\u00a0higher prevalence in certain high-risk groups such as type 1 diabetes mellitus, Down syndrome, Turner syndrome, IgA deficiency, William syndrome, and in first-degree relatives of celiac disease. [8] [15]", "contents": "Steatorrhea -- Epidemiology. The prevalence of celiac disease is on the rise, and a recent study reported a global seroprevalence of 1.4%. [14] Also, there are differences in the prevalence depending on geographical location. Reports of a biopsy-proven celiac disease show lower prevalence rates in South America and Africa and higher rates in Europe and Oceania. [14] For example, in Europe, Germany has a lower prevalence of celiac disease, and the highest prevalence was in Sweden and Finland. [14] Celiac disease has a\u00a0higher prevalence in certain high-risk groups such as type 1 diabetes mellitus, Down syndrome, Turner syndrome, IgA deficiency, William syndrome, and in first-degree relatives of celiac disease. [8] [15]"}
{"id": "article-29474_10", "title": "Steatorrhea -- Epidemiology", "content": "Based on a study from the\u00a0Netherlands, PBC had an incidence of 1.1 per 100000 (male to female ratio\u00a0was 1 to 6.3), and the point prevalence was 13.2 per 100000 individuals in 2008. [16] Another study from the U.S. reported an overall\u00a0incidence of PBC as\u00a02.7 per 100000 person-years and age and sex-adjusted\u00a0prevalence of 40 per 100000 with a\u00a0similar female predilection. [17] PSC has a prevalence rate depending on the geographical\u00a0location. A systematic review reported the incidence and prevalence rates of PSC\u00a0ranging from 0 to 1.3 per 100000\u00a0people per year and 0 to 16 per 100000 people, respectively. [18] As there is no consensus on the definition of SIBO, its exact prevalence is unknown. [11]", "contents": "Steatorrhea -- Epidemiology. Based on a study from the\u00a0Netherlands, PBC had an incidence of 1.1 per 100000 (male to female ratio\u00a0was 1 to 6.3), and the point prevalence was 13.2 per 100000 individuals in 2008. [16] Another study from the U.S. reported an overall\u00a0incidence of PBC as\u00a02.7 per 100000 person-years and age and sex-adjusted\u00a0prevalence of 40 per 100000 with a\u00a0similar female predilection. [17] PSC has a prevalence rate depending on the geographical\u00a0location. A systematic review reported the incidence and prevalence rates of PSC\u00a0ranging from 0 to 1.3 per 100000\u00a0people per year and 0 to 16 per 100000 people, respectively. [18] As there is no consensus on the definition of SIBO, its exact prevalence is unknown. [11]"}
{"id": "article-29474_11", "title": "Steatorrhea -- Pathophysiology", "content": "EPI: Chronic exposure to alcohol is\u00a0the most common etiological factor\u00a0for chronic pancreatitis. The other notable\u00a0risk factors for chronic pancreatitis include predisposing genetic mutations ( PRSS-1, SPINK-1, CFTR, CTRC), autoimmune pancreatitis, pancreatic duct obstruction, and chronic nicotine exposure. [19] The exact\u00a0pathophysiological\u00a0pathways underlying chronic pancreatitis are unclear but may include\u00a0mechanisms such as\u00a0chronic ongoing parenchymal\u00a0inflammation with acinar cell destruction, and\u00a0ductal dysfunction, etc. [19] The histopathological changes include pancreatic\u00a0atrophy\u00a0with fibrous scarring, which may be focal or diffuse. [20]", "contents": "Steatorrhea -- Pathophysiology. EPI: Chronic exposure to alcohol is\u00a0the most common etiological factor\u00a0for chronic pancreatitis. The other notable\u00a0risk factors for chronic pancreatitis include predisposing genetic mutations ( PRSS-1, SPINK-1, CFTR, CTRC), autoimmune pancreatitis, pancreatic duct obstruction, and chronic nicotine exposure. [19] The exact\u00a0pathophysiological\u00a0pathways underlying chronic pancreatitis are unclear but may include\u00a0mechanisms such as\u00a0chronic ongoing parenchymal\u00a0inflammation with acinar cell destruction, and\u00a0ductal dysfunction, etc. [19] The histopathological changes include pancreatic\u00a0atrophy\u00a0with fibrous scarring, which may be focal or diffuse. [20]"}
{"id": "article-29474_12", "title": "Steatorrhea -- Pathophysiology", "content": "CF is a multisystem disease as a result of mutations in the gene which\u00a0encodes\u00a0the\u00a0CF transmembrane conductance\u00a0regulator\u00a0(CFTR). [13] In the pancreas, CFTR dysfunction results in thick viscous\u00a0secretions along with defective bicarbonate flow resulting in EPI.", "contents": "Steatorrhea -- Pathophysiology. CF is a multisystem disease as a result of mutations in the gene which\u00a0encodes\u00a0the\u00a0CF transmembrane conductance\u00a0regulator\u00a0(CFTR). [13] In the pancreas, CFTR dysfunction results in thick viscous\u00a0secretions along with defective bicarbonate flow resulting in EPI."}
{"id": "article-29474_13", "title": "Steatorrhea -- Pathophysiology", "content": "Cholestatic Diseases: The mechanisms underlying the development of chronic cholestatic liver diseases, including PBC and PSC, are not entirely understood. Both these\u00a0disorders are characterized by portal inflammation and progressive fibrosis and eventually resulting in end-stage liver disease. Here, the reduction in bile flow results in the accumulation of toxic bile products, which leads to biliary epithelial damage. [21] This decrease in\u00a0bile reaching the\u00a0small\u00a0bowel interferes with fat absorption and causes\u00a0steatorrhea in these patients.", "contents": "Steatorrhea -- Pathophysiology. Cholestatic Diseases: The mechanisms underlying the development of chronic cholestatic liver diseases, including PBC and PSC, are not entirely understood. Both these\u00a0disorders are characterized by portal inflammation and progressive fibrosis and eventually resulting in end-stage liver disease. Here, the reduction in bile flow results in the accumulation of toxic bile products, which leads to biliary epithelial damage. [21] This decrease in\u00a0bile reaching the\u00a0small\u00a0bowel interferes with fat absorption and causes\u00a0steatorrhea in these patients."}
{"id": "article-29474_14", "title": "Steatorrhea -- Pathophysiology", "content": "Celiac Disease: It\u00a0is a chronic autoimmune-mediated\u00a0enteropathy related to exposure\u00a0to dietary gluten\u00a0in genetically susceptible individuals. The genes which encode for major histocompatibility complex (MHC) class II proteins HLA-DQ2 and HLA-DQ8 are\u00a0prerequisites for this disease.\u00a0Ingestion of gluten (specifically the gliadin\u00a0peptides from wheat, rye, and barley) by susceptible individuals, along with\u00a0some unknown trigger factors, leads to pathogenesis. [8] Gliadin polypeptides are resistant to degradation in the gastrointestinal tract and\u00a0can cross the small intestinal epithelial barrier. In the lamina propria,\u00a0these peptides get deamidated by local extracellular tissue transglutaminase (TTG). [8] This deamidation increases the affinity of gliadin binding to the antigen-binding groove of HLA DQ2 or HLA DQ8 on antigen-presenting cells. Upon presentation to CD4+ T lymphocytes, the gliadin peptides\u00a0trigger an immune response causing local inflammation, which results in the destruction of villi. In addition to adaptive immune dysfunction, patients with celiac disease also\u00a0have defects in innate intestinal immunity. The histopathological changes include increased intraepithelial lymphocytes, intestinal\u00a0villous atrophy (blunting or flattening of the villi), and crypt hyperplasia (elongation of the crypts). [22] These\u00a0changes\u00a0lead to the malabsorption of fats and fat-soluble vitamins.", "contents": "Steatorrhea -- Pathophysiology. Celiac Disease: It\u00a0is a chronic autoimmune-mediated\u00a0enteropathy related to exposure\u00a0to dietary gluten\u00a0in genetically susceptible individuals. The genes which encode for major histocompatibility complex (MHC) class II proteins HLA-DQ2 and HLA-DQ8 are\u00a0prerequisites for this disease.\u00a0Ingestion of gluten (specifically the gliadin\u00a0peptides from wheat, rye, and barley) by susceptible individuals, along with\u00a0some unknown trigger factors, leads to pathogenesis. [8] Gliadin polypeptides are resistant to degradation in the gastrointestinal tract and\u00a0can cross the small intestinal epithelial barrier. In the lamina propria,\u00a0these peptides get deamidated by local extracellular tissue transglutaminase (TTG). [8] This deamidation increases the affinity of gliadin binding to the antigen-binding groove of HLA DQ2 or HLA DQ8 on antigen-presenting cells. Upon presentation to CD4+ T lymphocytes, the gliadin peptides\u00a0trigger an immune response causing local inflammation, which results in the destruction of villi. In addition to adaptive immune dysfunction, patients with celiac disease also\u00a0have defects in innate intestinal immunity. The histopathological changes include increased intraepithelial lymphocytes, intestinal\u00a0villous atrophy (blunting or flattening of the villi), and crypt hyperplasia (elongation of the crypts). [22] These\u00a0changes\u00a0lead to the malabsorption of fats and fat-soluble vitamins."}
{"id": "article-29474_15", "title": "Steatorrhea -- Pathophysiology", "content": "SIBO: Under physiological conditions,\u00a0several defense\u00a0mechanisms regulate the microbiota in the gastrointestinal tract and prevent small intestine bacterial overgrowth. The\u00a0significant factors in SIBO prevention\u00a0include immunoglobin A,\u00a0gastric acidity, bile, and\u00a0defensins. [23] The aboral\u00a0peristalsis with migratory motor complexes\u00a0and an intact ileocaecal valve\u00a0also play a vital role in preventing SIBO. [23] Any\u00a0disturbances\u00a0in these\u00a0mechanisms could result in bacterial overgrowth. [23] [11] Deconjugation of bile\u00a0acids causes fat malabsorption along with\u00a0other factors such as ongoing inflammation, increased intestinal permeability. [23] [11]", "contents": "Steatorrhea -- Pathophysiology. SIBO: Under physiological conditions,\u00a0several defense\u00a0mechanisms regulate the microbiota in the gastrointestinal tract and prevent small intestine bacterial overgrowth. The\u00a0significant factors in SIBO prevention\u00a0include immunoglobin A,\u00a0gastric acidity, bile, and\u00a0defensins. [23] The aboral\u00a0peristalsis with migratory motor complexes\u00a0and an intact ileocaecal valve\u00a0also play a vital role in preventing SIBO. [23] Any\u00a0disturbances\u00a0in these\u00a0mechanisms could result in bacterial overgrowth. [23] [11] Deconjugation of bile\u00a0acids causes fat malabsorption along with\u00a0other factors such as ongoing inflammation, increased intestinal permeability. [23] [11]"}
{"id": "article-29474_16", "title": "Steatorrhea -- History and Physical", "content": "Patients with steatorrhea present with bulky, pale, foul-smelling oily stools. These fatty stools tend to float in the toilet bowl and often challenging to flush\u00a0as well. In the\u00a0early stages, steatorrhea may be asymptomatic and go unnoticed.\u00a0Patients also have other\u00a0nonspecific manifestations of fat malabsorption\u00a0such as chronic diarrhea, abdominal discomfort, bloating sensation,\u00a0and\u00a0weight loss.\u00a0Children may present with growth failure and delayed puberty.\u00a0In severe cases,\u00a0loss of subcutaneous\u00a0fat and muscle wasting may be evident. Manifestations of fat-soluble vitamin (A, D, E, and K)\u00a0deficiencies\u00a0can accompany fat malabsorption. Celiac patients can present with a variety of\u00a0extraintestinal signs such as anemia, oral ulcers, and\u00a0dermatitis herpetiformis rash. Abdominal pain is a predominant symptom in patients with chronic pancreatitis but also\u00a0reported in other conditions such as SIBO, inflammatory bowel disease,\u00a0and celiac disease.\u00a0CF patients have sinopulmonary manifestations. Jaundice, fatigue,\u00a0and pruritis are suggestive of cholestatic liver diseases such as PBC or PSC. Signs for end-stage liver disease such as splenomegaly, ascites can be noted in PBC or PSC.", "contents": "Steatorrhea -- History and Physical. Patients with steatorrhea present with bulky, pale, foul-smelling oily stools. These fatty stools tend to float in the toilet bowl and often challenging to flush\u00a0as well. In the\u00a0early stages, steatorrhea may be asymptomatic and go unnoticed.\u00a0Patients also have other\u00a0nonspecific manifestations of fat malabsorption\u00a0such as chronic diarrhea, abdominal discomfort, bloating sensation,\u00a0and\u00a0weight loss.\u00a0Children may present with growth failure and delayed puberty.\u00a0In severe cases,\u00a0loss of subcutaneous\u00a0fat and muscle wasting may be evident. Manifestations of fat-soluble vitamin (A, D, E, and K)\u00a0deficiencies\u00a0can accompany fat malabsorption. Celiac patients can present with a variety of\u00a0extraintestinal signs such as anemia, oral ulcers, and\u00a0dermatitis herpetiformis rash. Abdominal pain is a predominant symptom in patients with chronic pancreatitis but also\u00a0reported in other conditions such as SIBO, inflammatory bowel disease,\u00a0and celiac disease.\u00a0CF patients have sinopulmonary manifestations. Jaundice, fatigue,\u00a0and pruritis are suggestive of cholestatic liver diseases such as PBC or PSC. Signs for end-stage liver disease such as splenomegaly, ascites can be noted in PBC or PSC."}
{"id": "article-29474_17", "title": "Steatorrhea -- Evaluation", "content": "The diagnosis of steatorrhea is based on clinical findings, laboratory tests, and radiological images. Endoscopy with\u00a0small intestinal biopsy,\u00a0liver biopsy,\u00a0and other specialized investigations may be needed to detect the exact\u00a0etiology of steatorrhea.", "contents": "Steatorrhea -- Evaluation. The diagnosis of steatorrhea is based on clinical findings, laboratory tests, and radiological images. Endoscopy with\u00a0small intestinal biopsy,\u00a0liver biopsy,\u00a0and other specialized investigations may be needed to detect the exact\u00a0etiology of steatorrhea."}
{"id": "article-29474_18", "title": "Steatorrhea -- Evaluation", "content": "Quantitative estimation of fecal fat (exceeding 7 g per 24 hours) is an essential first step for the diagnosis of steatorrhea. The standard method of fecal fat quantification is by calculating the coefficient of fat absorption (CFA). [24] With\u00a0a standard\u00a0quantity of fat ingestion, CFA is the percentage of dietary\u00a0fat\u00a0that is absorbed. [24] Patients should follow a strict diet for\u00a0five days containing 100 g of fats daily. [24] Stools are collected in the last 72-hour for fecal fat estimation. CFA over 92% is considered normal. [24] Even though accurate, this method is cumbersome and\u00a0unpleasant for most patients. For evaluation of EPI, fecal elastase may be\u00a0utilized\u00a0instead of the 72-hour fecal fat testing. A value of more than 200 mcg/g of stool is\u00a0considered normal; 100 to 200 mcg/g is indeterminate,\u00a0and\u00a0less than 100 mcg/g is abnormal\u00a0and indicative of EPI.\u00a0Here the\u00a0advantage is the\u00a0requirement of\u00a0a single stool sample.\u00a0However, in the\u00a0early stages of EPI, this test has a\u00a0lower sensitivity. Also, a\u00a0formed stool is necessary for testing. Otherwise, the fecal elastase could be falsely low due to dilution.", "contents": "Steatorrhea -- Evaluation. Quantitative estimation of fecal fat (exceeding 7 g per 24 hours) is an essential first step for the diagnosis of steatorrhea. The standard method of fecal fat quantification is by calculating the coefficient of fat absorption (CFA). [24] With\u00a0a standard\u00a0quantity of fat ingestion, CFA is the percentage of dietary\u00a0fat\u00a0that is absorbed. [24] Patients should follow a strict diet for\u00a0five days containing 100 g of fats daily. [24] Stools are collected in the last 72-hour for fecal fat estimation. CFA over 92% is considered normal. [24] Even though accurate, this method is cumbersome and\u00a0unpleasant for most patients. For evaluation of EPI, fecal elastase may be\u00a0utilized\u00a0instead of the 72-hour fecal fat testing. A value of more than 200 mcg/g of stool is\u00a0considered normal; 100 to 200 mcg/g is indeterminate,\u00a0and\u00a0less than 100 mcg/g is abnormal\u00a0and indicative of EPI.\u00a0Here the\u00a0advantage is the\u00a0requirement of\u00a0a single stool sample.\u00a0However, in the\u00a0early stages of EPI, this test has a\u00a0lower sensitivity. Also, a\u00a0formed stool is necessary for testing. Otherwise, the fecal elastase could be falsely low due to dilution."}
{"id": "article-29474_19", "title": "Steatorrhea -- Evaluation", "content": "For evaluation of\u00a0chronic pancreatitis, a plain abdominal radiograph may show pancreatic calcification, abdominal CT or MRI scans may reveal calcifications of chronic pancreatitis and ductal dilatation, magnetic resonance cholangiopancreatography (MRCP)\u00a0or endoscopic retrograde cholangiopancreatography (ERCP) can offer a more detailed evaluation of pancreatic parenchymal and ductal changes in chronic pancreatitis. [25] [26] Similarly, MRCP, ERCP, and endoscopic ultrasound (EUS) are indispensable in the evaluation of pancreatic tumors.", "contents": "Steatorrhea -- Evaluation. For evaluation of\u00a0chronic pancreatitis, a plain abdominal radiograph may show pancreatic calcification, abdominal CT or MRI scans may reveal calcifications of chronic pancreatitis and ductal dilatation, magnetic resonance cholangiopancreatography (MRCP)\u00a0or endoscopic retrograde cholangiopancreatography (ERCP) can offer a more detailed evaluation of pancreatic parenchymal and ductal changes in chronic pancreatitis. [25] [26] Similarly, MRCP, ERCP, and endoscopic ultrasound (EUS) are indispensable in the evaluation of pancreatic tumors."}
{"id": "article-29474_20", "title": "Steatorrhea -- Evaluation", "content": "For evaluation of celiac disease, estimation of serum\u00a0tissue transglutaminase\u00a0IgA\u00a0antibodies (TTG-IgA) with total serum IgA is the recommended\u00a0screening test. [8] IgA endomysial antibodies (EMA-IgA)\u00a0has the highest specificity and is an option if TTG-IgA is weakly positive. [8] In patients with IgA deficiency, both TTG-IgA and EMA-IgA may be falsely low. In this population, TTG-IgG and deamidated gliadin peptide IgG (DGP-IgG) are the recommendations for screening. [8] Patients with positive serological tests should be followed up with\u00a0duodenal biopsies for confirmation. [8]", "contents": "Steatorrhea -- Evaluation. For evaluation of celiac disease, estimation of serum\u00a0tissue transglutaminase\u00a0IgA\u00a0antibodies (TTG-IgA) with total serum IgA is the recommended\u00a0screening test. [8] IgA endomysial antibodies (EMA-IgA)\u00a0has the highest specificity and is an option if TTG-IgA is weakly positive. [8] In patients with IgA deficiency, both TTG-IgA and EMA-IgA may be falsely low. In this population, TTG-IgG and deamidated gliadin peptide IgG (DGP-IgG) are the recommendations for screening. [8] Patients with positive serological tests should be followed up with\u00a0duodenal biopsies for confirmation. [8]"}
{"id": "article-29474_21", "title": "Steatorrhea -- Evaluation", "content": "In patients suspected to have chronic liver disease, serum liver tests may reflect a cholestatic pattern, elevation of alkaline phosphatase and gamma-glutamyl transferase are\u00a0frequent findings in both PBC and PSC. AST,\u00a0ALT, and bilirubin may be normal or\u00a0elevated. Anti-mitochondrial antibodies are\u00a0noted in 90 to 95% of patients with PBC. [27] Liver biopsy is not routinely needed for the\u00a0diagnosis\u00a0of PBC.\u00a0If done, a liver biopsy may show the destruction of interlobular bile ducts and cirrhotic changes in the\u00a0later stages.", "contents": "Steatorrhea -- Evaluation. In patients suspected to have chronic liver disease, serum liver tests may reflect a cholestatic pattern, elevation of alkaline phosphatase and gamma-glutamyl transferase are\u00a0frequent findings in both PBC and PSC. AST,\u00a0ALT, and bilirubin may be normal or\u00a0elevated. Anti-mitochondrial antibodies are\u00a0noted in 90 to 95% of patients with PBC. [27] Liver biopsy is not routinely needed for the\u00a0diagnosis\u00a0of PBC.\u00a0If done, a liver biopsy may show the destruction of interlobular bile ducts and cirrhotic changes in the\u00a0later stages."}
{"id": "article-29474_22", "title": "Steatorrhea -- Evaluation", "content": "In PSC, magnetic resonance cholangiography (MRC)\u00a0is the preferred modality and may show a\u00a0multifocal narrowing of both intrahepatic and extrahepatic biliary ductal strictures. These strictures may be seen alternating with dilation, which is referred to\u00a0as the \"beaded\" appearance. [28] ERCP or percutaneous transhepatic cholangiography\u00a0is also helpful to delineate the biliary anatomy in PSC but not routinely utilized for the\u00a0diagnosis due to their invasiveness. [28] In PSC, a liver biopsy is not a routine test, and when done, may\u00a0demonstrate periductular fibrosis (onion skin fibrosis). [28] Even though specific, this finding is infrequent. [28] In PSC, a\u00a0liver biopsy may be helpful in\u00a0a few particular circumstances, such as for the\u00a0evaluation of small duct PSC and also to exclude coexistent autoimmune hepatitis, which is referred to\u00a0as overlap syndrome. [28] About 80% of\u00a0patients with PSC have IBD.\u00a0Due to this strong association, if previously undiagnosed, a workup for IBD is recommended at the time of diagnosis of PSC.", "contents": "Steatorrhea -- Evaluation. In PSC, magnetic resonance cholangiography (MRC)\u00a0is the preferred modality and may show a\u00a0multifocal narrowing of both intrahepatic and extrahepatic biliary ductal strictures. These strictures may be seen alternating with dilation, which is referred to\u00a0as the \"beaded\" appearance. [28] ERCP or percutaneous transhepatic cholangiography\u00a0is also helpful to delineate the biliary anatomy in PSC but not routinely utilized for the\u00a0diagnosis due to their invasiveness. [28] In PSC, a liver biopsy is not a routine test, and when done, may\u00a0demonstrate periductular fibrosis (onion skin fibrosis). [28] Even though specific, this finding is infrequent. [28] In PSC, a\u00a0liver biopsy may be helpful in\u00a0a few particular circumstances, such as for the\u00a0evaluation of small duct PSC and also to exclude coexistent autoimmune hepatitis, which is referred to\u00a0as overlap syndrome. [28] About 80% of\u00a0patients with PSC have IBD.\u00a0Due to this strong association, if previously undiagnosed, a workup for IBD is recommended at the time of diagnosis of PSC."}
{"id": "article-29474_23", "title": "Steatorrhea -- Evaluation", "content": "Endoscopy with direct aspiration and culture of the small intestinal contents was traditionally the gold standard test for SIBO. [11] However, due to its invasive nature and lack of consensus on the definition regarding SIBO, this method is less preferred. [11] Breath tests utilizing either glucose or lactulose\u00a0are commonly used in clinical practice. [11]", "contents": "Steatorrhea -- Evaluation. Endoscopy with direct aspiration and culture of the small intestinal contents was traditionally the gold standard test for SIBO. [11] However, due to its invasive nature and lack of consensus on the definition regarding SIBO, this method is less preferred. [11] Breath tests utilizing either glucose or lactulose\u00a0are commonly used in clinical practice. [11]"}
{"id": "article-29474_24", "title": "Steatorrhea -- Treatment / Management", "content": "Treatment of steatorrhea depends on the underlying conditions which cause steatorrhea.", "contents": "Steatorrhea -- Treatment / Management. Treatment of steatorrhea depends on the underlying conditions which cause steatorrhea."}
{"id": "article-29474_25", "title": "Steatorrhea -- Treatment / Management", "content": "In patients with EPI, pancreatic enzyme replacement therapy (PERT)\u00a0is the\u00a0cornerstone of treatment. [29]", "contents": "Steatorrhea -- Treatment / Management. In patients with EPI, pancreatic enzyme replacement therapy (PERT)\u00a0is the\u00a0cornerstone of treatment. [29]"}
{"id": "article-29474_26", "title": "Steatorrhea -- Treatment / Management", "content": "Along with PERT,\u00a0patients with EPI\u00a0should receive normal to a high-fat diet\u00a0and fat-soluble vitamin supplementation. [3] Fat restriction may improve the symptoms associated with steatorrhea but will worsen the nutritional status and is\u00a0no longer a recommendation.", "contents": "Steatorrhea -- Treatment / Management. Along with PERT,\u00a0patients with EPI\u00a0should receive normal to a high-fat diet\u00a0and fat-soluble vitamin supplementation. [3] Fat restriction may improve the symptoms associated with steatorrhea but will worsen the nutritional status and is\u00a0no longer a recommendation."}
{"id": "article-29474_27", "title": "Steatorrhea -- Treatment / Management", "content": "In patients with SIBO, an empiric trial of antibiotics is recommended.\u00a0In many institutions, rifaximin is preferable to other antibiotics such as\u00a0ciprofloxacin, metronidazole,\u00a0norfloxacin, doxycycline, and\u00a0amoxicillin-clavulanic acid. [23] [11]", "contents": "Steatorrhea -- Treatment / Management. In patients with SIBO, an empiric trial of antibiotics is recommended.\u00a0In many institutions, rifaximin is preferable to other antibiotics such as\u00a0ciprofloxacin, metronidazole,\u00a0norfloxacin, doxycycline, and\u00a0amoxicillin-clavulanic acid. [23] [11]"}
{"id": "article-29474_28", "title": "Steatorrhea -- Treatment / Management", "content": "In patients with celiac disease, diet-centered recommendations include a\u00a0strict life-long gluten-free diet, education about the disease, management of nutritional deficiencies, access to an advocacy group, and consultation with a skilled dietitian. [22]", "contents": "Steatorrhea -- Treatment / Management. In patients with celiac disease, diet-centered recommendations include a\u00a0strict life-long gluten-free diet, education about the disease, management of nutritional deficiencies, access to an advocacy group, and consultation with a skilled dietitian. [22]"}
{"id": "article-29474_29", "title": "Steatorrhea -- Treatment / Management", "content": "Ursodeoxycholic acid is the first-line treatment of choice for PBC. [30] About 40% of patients may not respond to ursodeoxycholic acid\u00a0and may eventually need a\u00a0liver transplant. [30]", "contents": "Steatorrhea -- Treatment / Management. Ursodeoxycholic acid is the first-line treatment of choice for PBC. [30] About 40% of patients may not respond to ursodeoxycholic acid\u00a0and may eventually need a\u00a0liver transplant. [30]"}
{"id": "article-29474_30", "title": "Steatorrhea -- Treatment / Management", "content": "Even though ursodeoxycholic acid is often used in PSC, medical therapy is not effective in curtailing the disease\u00a0progression. ERCP with stent dilatation is useful for symptomatic improvement in\u00a0biliary ductal strictures\u00a0in large intrahepatic or extrahepatic ducts. [28] Liver transplantation is the definitive treatment for PSC\u00a0and,\u00a0post-transplant recurrence is not uncommon.", "contents": "Steatorrhea -- Treatment / Management. Even though ursodeoxycholic acid is often used in PSC, medical therapy is not effective in curtailing the disease\u00a0progression. ERCP with stent dilatation is useful for symptomatic improvement in\u00a0biliary ductal strictures\u00a0in large intrahepatic or extrahepatic ducts. [28] Liver transplantation is the definitive treatment for PSC\u00a0and,\u00a0post-transplant recurrence is not uncommon."}
{"id": "article-29474_31", "title": "Steatorrhea -- Differential Diagnosis", "content": "When assessing a patient with steatorrhea, the following conditions must be considered and ruled out: Alcoholic pancreatitis Hereditary\u00a0pancreatitis (mutations in\u00a0genes such as PRSS-1, SPINK-1, CFTR, CTRC ) Pancreatic insufficiency due to inherited conditions such as CF, Shwachman-Diamond syndrome, Pearson marrow syndrome,\u00a0 and Johanson\u2013Blizzard syndrome Celiac disease Tropical sprue Chronic liver diseases such as PBC,\u00a0PSC Advanced pancreatic cancer Distal\u00a0ileal pathology (e.g., Crohn disease)\u00a0or resection Giardiasis Whipple disease SIBO Following is the list of conditions that present with chronic diarrhea which can be mistaken for steatorrhea: Irritable bowel syndrome Carbohydrate malabsorption (e.g., lactose intolerance, fructose malabsorption) Chronic laxative abuse Chronic or recurrent\u00a0gastrointestinal infections Withdrawal of opioids Endocrine causes (hyperthyroidism, Addisons disease, neuroendocrine tumors)", "contents": "Steatorrhea -- Differential Diagnosis. When assessing a patient with steatorrhea, the following conditions must be considered and ruled out: Alcoholic pancreatitis Hereditary\u00a0pancreatitis (mutations in\u00a0genes such as PRSS-1, SPINK-1, CFTR, CTRC ) Pancreatic insufficiency due to inherited conditions such as CF, Shwachman-Diamond syndrome, Pearson marrow syndrome,\u00a0 and Johanson\u2013Blizzard syndrome Celiac disease Tropical sprue Chronic liver diseases such as PBC,\u00a0PSC Advanced pancreatic cancer Distal\u00a0ileal pathology (e.g., Crohn disease)\u00a0or resection Giardiasis Whipple disease SIBO Following is the list of conditions that present with chronic diarrhea which can be mistaken for steatorrhea: Irritable bowel syndrome Carbohydrate malabsorption (e.g., lactose intolerance, fructose malabsorption) Chronic laxative abuse Chronic or recurrent\u00a0gastrointestinal infections Withdrawal of opioids Endocrine causes (hyperthyroidism, Addisons disease, neuroendocrine tumors)"}
{"id": "article-29474_32", "title": "Steatorrhea -- Prognosis", "content": "The prognosis of steatorrhea depends on the underlying etiology. Steatorrhea due to exocrine pancreatic insufficiency and disorders of the small intestine like celiac disease, tropical sprue, or giardiasis has a good prognosis. But steatorrhea due to\u00a0 CF and bile salt deficiencies like in PSC and PBC has a poor prognosis because of the progressive nature of underlying etiologies.", "contents": "Steatorrhea -- Prognosis. The prognosis of steatorrhea depends on the underlying etiology. Steatorrhea due to exocrine pancreatic insufficiency and disorders of the small intestine like celiac disease, tropical sprue, or giardiasis has a good prognosis. But steatorrhea due to\u00a0 CF and bile salt deficiencies like in PSC and PBC has a poor prognosis because of the progressive nature of underlying etiologies."}
{"id": "article-29474_33", "title": "Steatorrhea -- Complications", "content": "Different causes of steatorrhea lead to different complications. Following are some complications that can occur due to steatorrhea:", "contents": "Steatorrhea -- Complications. Different causes of steatorrhea lead to different complications. Following are some complications that can occur due to steatorrhea:"}
{"id": "article-29474_34", "title": "Steatorrhea -- Complications", "content": "Weight loss in adults and other consequences of malnutrition such as increased susceptibility to infections, and\u00a0increased morbidity and mortality from various disease states.\u00a0Additionally, in children, malnutrition results in growth failure and poor neurological development Deficiencies\u00a0of fat-soluble vitamins (A, D, E, and K) Poor bone health resulting in osteopenia, osteoporosis, and fractures\u00a0(CF, celiac disease) Iron deficiency anemia, zinc deficiency (celiac disease) Dermatitis herpetiformis,\u00a0non-Hodgkin lymphoma,\u00a0adenocarcinoma of the upper gastrointestinal tract (celiac disease) Megaloblastic anemia due to B12 deficiency\u00a0(in terminal ileum disease and SIBO) Pancreatic pseudocyst, ascites, splenic vein thrombosis, diabetes, pancreatic cancer (chronic pancreatitis) Seizure, osteopenia, ataxia, early bruising, headache, hyposplenism, and tetany (celiac disease) Cirrhosis, end-stage liver disease (PBC, PSC), malignancies such as cholangiocarcinoma, colon cancer in PSC", "contents": "Steatorrhea -- Complications. Weight loss in adults and other consequences of malnutrition such as increased susceptibility to infections, and\u00a0increased morbidity and mortality from various disease states.\u00a0Additionally, in children, malnutrition results in growth failure and poor neurological development Deficiencies\u00a0of fat-soluble vitamins (A, D, E, and K) Poor bone health resulting in osteopenia, osteoporosis, and fractures\u00a0(CF, celiac disease) Iron deficiency anemia, zinc deficiency (celiac disease) Dermatitis herpetiformis,\u00a0non-Hodgkin lymphoma,\u00a0adenocarcinoma of the upper gastrointestinal tract (celiac disease) Megaloblastic anemia due to B12 deficiency\u00a0(in terminal ileum disease and SIBO) Pancreatic pseudocyst, ascites, splenic vein thrombosis, diabetes, pancreatic cancer (chronic pancreatitis) Seizure, osteopenia, ataxia, early bruising, headache, hyposplenism, and tetany (celiac disease) Cirrhosis, end-stage liver disease (PBC, PSC), malignancies such as cholangiocarcinoma, colon cancer in PSC"}
{"id": "article-29474_35", "title": "Steatorrhea -- Deterrence and Patient Education", "content": "Patient education is very important in steatorrhea. Dietary counseling should be done by nutritionist regarding intake of fat and fat-soluble vitamins. It was advised earlier to decrease fat intake in patients with exocrine pancreatic insufficiency that helps in decreasing stool volume but it has been found that it causes malnutrition. So normal to high-fat diet with pancreatic enzyme replacement is advised in such patients. Similarly, dietary counseling in patients with celiac disease is essential.", "contents": "Steatorrhea -- Deterrence and Patient Education. Patient education is very important in steatorrhea. Dietary counseling should be done by nutritionist regarding intake of fat and fat-soluble vitamins. It was advised earlier to decrease fat intake in patients with exocrine pancreatic insufficiency that helps in decreasing stool volume but it has been found that it causes malnutrition. So normal to high-fat diet with pancreatic enzyme replacement is advised in such patients. Similarly, dietary counseling in patients with celiac disease is essential."}
{"id": "article-29474_36", "title": "Steatorrhea -- Pearls and Other Issues", "content": "Untreated steatorrhea leads\u00a0to malnutrition and other\u00a0complications such as\u00a0fat-soluble vitamin deficiencies (A, D, E, and K). Identifying the cause of steatorrhea is vital for proper management and prevention of these\u00a0complications. [31]", "contents": "Steatorrhea -- Pearls and Other Issues. Untreated steatorrhea leads\u00a0to malnutrition and other\u00a0complications such as\u00a0fat-soluble vitamin deficiencies (A, D, E, and K). Identifying the cause of steatorrhea is vital for proper management and prevention of these\u00a0complications. [31]"}
{"id": "article-29474_37", "title": "Steatorrhea -- Enhancing Healthcare Team Outcomes", "content": "The diagnosis of steatorrhea is usually delayed for months\u00a0to years due to non-specific or minimal\u00a0presenting symptoms during the\u00a0early stages. An interprofessional team approach is often necessary for diagnosis, treatment, and follow-up. If steatorrhea is suspected clinically, the provider and nurse practitioner should refer the patient to a gastroenterologist for consultation. As numerous conditions could contribute to steatorrhea, a systematic evaluation is required to expedite the\u00a0diagnosis and to prevent further\u00a0complications. The team should also include specialty-trained nurses and pharmacists to assist with patient monitoring and education. The involvement of a skilled dietician is\u00a0indispensable for\u00a0enhancing the nutritional status\u00a0and limiting further malnutrition-related adverse outcomes.[Level V]", "contents": "Steatorrhea -- Enhancing Healthcare Team Outcomes. The diagnosis of steatorrhea is usually delayed for months\u00a0to years due to non-specific or minimal\u00a0presenting symptoms during the\u00a0early stages. An interprofessional team approach is often necessary for diagnosis, treatment, and follow-up. If steatorrhea is suspected clinically, the provider and nurse practitioner should refer the patient to a gastroenterologist for consultation. As numerous conditions could contribute to steatorrhea, a systematic evaluation is required to expedite the\u00a0diagnosis and to prevent further\u00a0complications. The team should also include specialty-trained nurses and pharmacists to assist with patient monitoring and education. The involvement of a skilled dietician is\u00a0indispensable for\u00a0enhancing the nutritional status\u00a0and limiting further malnutrition-related adverse outcomes.[Level V]"}
{"id": "article-29474_38", "title": "Steatorrhea -- Review Questions", "content": "Access free multiple choice questions on this topic. Comment on this article.", "contents": "Steatorrhea -- Review Questions. Access free multiple choice questions on this topic. Comment on this article."}